- Verastem Oncology has had a relatively quiet year for most of 2021 but a pair of announcements has provided a burst of excitement that could revitalize investor sentiment.
- The company’s RAF/MEK dual inhibitor, VS-6766, continues to show encouraging results in LGSOC and NSCLC.
- Verastem and Amgen have teamed up to pit VS-6766+LUMAKRAS against NSCLC.
- I discuss my leading downside risks and how I plan to manage my position around them.
- I take a look at the charts to map out my next buy.
For further details see:
Verastem: Buying Opportunity Following Unjustified Sell-Off